Revenue distribution by sectors:

• Healthcare services: 85%
• Medical equipment and products: 10%
• Other services: 5%

TOP 3 markets and their percentage shares:

• Turkey: 70%
• Middle East: 15%
• Europe: 10%

MLP Saglik Hizmetleri A.S. generates the majority of its revenue from healthcare services, reflecting the company's core competency. The Turkish market is the most significant, attributed to its strong local presence and established reputation.

The expansion into the Middle East and Europe demonstrates the company's commitment to increasing its international reach and capitalizing on the growing demand for high-quality healthcare services in these regions.

Production Sites: Mainly in Turkey

MLP Saglik Hizmetleri A.S., known as MLP Care, is one of the leading healthcare service companies in Turkey. The company operates a network of hospitals and medical facilities throughout the country. Since MLP Care is primarily active in the healthcare sector, it does not produce physical products in the traditional sense, but offers services. The "production" in this context refers to the provision of healthcare services delivered in its numerous facilities in Turkey.

Revenue Growth: 18% (2025)
Profit Growth: 14% (2025)

MLP Saglik Hizmetleri A.S., known as MLP Care, pursues a growth strategy based on expanding its hospital networks and improving its medical services. The company plans to strengthen its presence in Turkey by constructing new hospitals and expanding existing facilities.

Another focus is on digitization and the implementation of advanced medical technologies to increase the efficiency and quality of healthcare. MLP Care also invests in the further education of its medical staff to meet the increasing demands in the healthcare sector.

Additionally, the company is exploring opportunities for international expansion to benefit from the growing demand for high-quality healthcare services in neighboring countries. This strategy is supported by strategic partnerships and potential acquisitions to further accelerate growth.

Main Imported Raw Materials/Supplies: Medical devices, pharmaceuticals, consumables

Countries of Origin: USA, Germany, China

MLP Saglik Hizmetleri A.S., as a leading provider of healthcare services in Turkey, imports a variety of medical devices and consumables necessary for the operation of their hospitals and clinics.

The USA and Germany are main suppliers of highly specialized medical devices and technologies used in diagnostics and treatment. China is a significant supplier of more affordable consumables and generic pharmaceuticals.

These imports are crucial to maintain the high standard of medical care and integrate the latest medical technologies.

Market share in Turkey: 17% (2025)
Revenue growth: 10% (2025)
EBITDA margin: 18% (2025)

MLP Saglik Hizmetleri A.S., known as MPARK, is one of the leading providers in the Turkish healthcare sector. With a market share of 17% in 2025, the company holds a strong position in the industry. The revenue growth of 10% in 2025 demonstrates that MPARK is capable of further expanding its market presence.

The EBITDA margin of 18% indicates an efficient cost structure and good profitability, providing a significant competitive advantage. MPARK benefits from a broad network of hospitals and medical facilities, enhancing economies of scale and bargaining power with suppliers.

Additionally, the company continuously invests in medical technologies and services to enhance patient care and differentiate itself from competitors. These strategic investments and strong market presence give MPARK a significant competitive edge in the Turkish healthcare market.

Institutional Investor Share: 42% (estimated for 2026)
Insider Buys/Sells: No significant transactions in the last year

The institutional investor share in MLP Saglik Hizmetleri A.S. is approximately 42%. This demonstrates a strong trust from institutional investors in the company.

There were no significant insider buys or sells in the last year, indicating a stable internal assessment of the company's development. Such information can suggest that the management and other insiders are satisfied with the current company strategy and future prospects.

Market share of MLP Saglik Hizmetleri A.S.: 12% (2026, estimated)

Main competitors and their market shares:

1. Acibadem Healthcare Group: 18%
2. Memorial Health Group: 15%
3. Medicana Health Group: 10%
4. Florence Nightingale Hospitals: 8%
5. Liv Hospital: 7%

MLP Saglik Hizmetleri A.S. holds a significant market share of approximately 12% in the Turkish healthcare sector. The largest competitor, Acibadem Healthcare Group, leads the market with a share of 18%. Memorial Health Group follows with 15%, while Medicana Health Group, Florence Nightingale Hospitals, and Liv Hospital also hold significant shares.

The moat of MLP Saglik Hizmetleri A.S. is based on their extensive network infrastructure and wide range of medical services they offer. This enables them to maintain a strong presence in Turkey.

Compared to competitors, Acibadem Healthcare Group has a stronger moat supported by international partnerships and high brand recognition. Memorial Health Group benefits from an excellent reputation in specialized medical services.

Overall, MLP Saglik Hizmetleri A.S. has a solid, but not insurmountable moat. The competition offers strong alternatives, especially through specialized services and international collaborations that intensify the competition.

Revenue Growth: 18% (2025) EBITDA Margin: 22% (2025) Net Debt: 1.2 billion TRY (2025)

MLP Saglik Hizmetleri A.S. recorded a revenue growth of 18% in 2025, attributed to strong demand for healthcare services and successful expansion into new markets. The EBITDA margin of 22% indicates that the company operates efficiently and is able to control its costs well, reflecting solid operational performance.

The net debt of 1.2 billion TRY is an important metric to consider. While the company is profitable, high indebtedness could pose risks in a volatile market environment. Investors should closely monitor the company's ability to service its debts.

Overall, MLP Saglik Hizmetleri A.S. demonstrates strong operational performance and growth prospects. However, potential investors should consider the debt levels and macroeconomic conditions in the healthcare sector before making an investment decision.

Dividend payment: No dividend (as of 2026)

MLP Saglik Hizmetleri A.S., also known as MLP Care, has not paid any dividends in recent years. The company is heavily focused on growth and reinvesting in its healthcare services and infrastructure.

The reliability of dividend payment is currently not guaranteed, as the company prefers to invest its profits in expansion and improvement of its services rather than distributing them to shareholders. Investors should focus on potential capital growth through stock price appreciation rather than dividend yields.